Breast Cancer New Reference: Pembrolizumab in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
Hepatocellular Carcinoma New Reference: Cabozantinib and Atezolizumab in HCC Ulas D. Bayraktar, MD 2022-11-26
Hodgkin Lymphoma New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma Ulas D. Bayraktar, MD 2022-11-26
Breast Cancer New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
Other diagnosis New Indication: Avelumab and Axitinib in Thymic Carcinoma Ulas D. Bayraktar, MD 2022-11-26
Non-Small Cell Lung Cancer New Indication: Adjuvant Pembrolizumab in NSCLC Ulas D. Bayraktar, MD 2022-11-26
Non-Small Cell Lung Cancer New Drug: Selpercatinib in RET-Fusion Positive NSCLC Ulas D. Bayraktar, MD 2022-11-26
Gastrointestinal Stromal Tumor New Drug: Ripretinib for Advanced GIST Ulas D. Bayraktar, MD 2022-09-20
